Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

Camurus said the FDA has accepted for review the resubmitted NDA for CAM2029 (octreotide), with a PDUFA target action date set for 18 Dec 2026. The acceptance advances the regulatory timeline toward a potential approval decision, which should be modestly supportive for sentiment despite no efficacy/safety outcome reported yet.